TEGA Therapeutics, Inc.
TEGA Therapeutics was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. The company specializes in glycans, complex carbohydrates that play important roles in physiological and pathophysiological processes. TEGA's pipeline includes recombinant production of heparan sulfate and enzyme replacement therapy to treat genetic deficiencies in degradation of heparan sulfate, aiming to develop therapies for lysosomal storage disorders and other related diseases.
Industries
Nr. of Employees
small (1-50)
TEGA Therapeutics, Inc.
3550 General Atomics Court, Suite G02-102, San Diego, CA 92121
Patents
Products
Recombinant heparan sulfate reagent series (rHS variants)
A catalog of recombinant heparan sulfate/glycosaminoglycan variants produced in mammalian cell culture with defined molecular weights, sulfate contents and functional properties; available in single-milligram units and sampler/combo packs for research use.
Recombinant heparan sulfate reagent series (rHS variants)
A catalog of recombinant heparan sulfate/glycosaminoglycan variants produced in mammalian cell culture with defined molecular weights, sulfate contents and functional properties; available in single-milligram units and sampler/combo packs for research use.
Services
Sale and distribution of multiple characterized recombinant heparan sulfate variants and sampler/combo packs for research use; products shipped as lyophilized powders with stated lead times and shipping options.
In-house development of recombinant glycosaminoglycans and enzyme replacement therapy approaches; grant-supported projects and scientific publications indicate capacity for preclinical collaboration or research partnerships.
Sale and distribution of multiple characterized recombinant heparan sulfate variants and sampler/combo packs for research use; products shipped as lyophilized powders with stated lead times and shipping options.
In-house development of recombinant glycosaminoglycans and enzyme replacement therapy approaches; grant-supported projects and scientific publications indicate capacity for preclinical collaboration or research partnerships.
Expertise Areas
- Glycobiology research
- Recombinant glycosaminoglycan production
- Metabolic engineering of mammalian cells
- Enzyme replacement therapy development for lysosomal storage disorders
Key Technologies
- Metabolic engineering of mammalian cells
- Multiplex genome editing
- Mammalian cell culture biomanufacturing
- Recombinant glycosaminoglycan synthesis
News & Updates
TEGA recombinant heparan sulfate (rHS09) was a potent inhibitor of SARS-CoV2 spike protein binding to human lung cells, published in the journal Cell.
TEGA Therapeutics was awarded a phase I SBIR grant from the National Institute of Neurological Disorders and Stroke for the project 'Intracerebroventricular alpha-N-acetylglucosaminidase Delivery to the Brain' to develop treatments for MPS IIIB.
TEGA Therapeutics was awarded a phase I SBIR grant from the National Science Foundation for the project 'Bioengineered Recombinant Anticoagulant Heparin' to produce anticoagulant heparin from cultured mammalian cells.
Dr. Glass reviews engineering the mammalian heparan sulfate biosynthetic pathway and therapeutic applications for bioengineered heparan sulfate in anticoagulation and beyond.
Dr. Thacker reviews progress in manipulating the heparan sulfate biosynthetic pathway to produce bioengineered heparan sulfates.
TEGA Therapeutics was awarded a phase I SBIR grant from the National Institute of Neurological Disorders and Stroke for the project 'Intracerebroventricular Iduronidase Delivery to the Brain' to investigate treatments for MPS I.
TEGA recombinant heparan sulfate (rHS09) was a potent inhibitor of SARS-CoV2 spike protein binding to human lung cells, published in the journal Cell.
TEGA Therapeutics was awarded a phase I SBIR grant from the National Institute of Neurological Disorders and Stroke for the project 'Intracerebroventricular alpha-N-acetylglucosaminidase Delivery to the Brain' to develop treatments for MPS IIIB.
TEGA Therapeutics was awarded a phase I SBIR grant from the National Science Foundation for the project 'Bioengineered Recombinant Anticoagulant Heparin' to produce anticoagulant heparin from cultured mammalian cells.
Dr. Glass reviews engineering the mammalian heparan sulfate biosynthetic pathway and therapeutic applications for bioengineered heparan sulfate in anticoagulation and beyond.
Dr. Thacker reviews progress in manipulating the heparan sulfate biosynthetic pathway to produce bioengineered heparan sulfates.
TEGA Therapeutics was awarded a phase I SBIR grant from the National Institute of Neurological Disorders and Stroke for the project 'Intracerebroventricular Iduronidase Delivery to the Brain' to investigate treatments for MPS I.